Tag Archive | Glaucoma

Chapter 243 – Complications of Glaucoma Surgery and Their Management

Chapter 243 – Complications of Glaucoma Surgery and Their Management   J. WILLIAM DOYLE M. FRAN SMITH   INTRODUCTION In the ideal world, surgery proceeds smoothly and outcomes are uncomplicated. Unfortunately, in the real world, despite a surgeon’s best efforts, complications may occur. This is especially true in the field of glaucoma—glaucoma surgery, unlike many […]

Chapter 241 – Antifibrotic Agents in Glaucoma Surgery

Chapter 241 – Antifibrotic Agents in Glaucoma Surgery   1596   PENG TEE KHAW LYDIA CHANG   INTRODUCTION One of the major areas of advance in the surgical management of glaucoma over the past 20 years has been the use of antimetabolites to prevent scarring after glaucoma filtration surgery. Antimetabolites have gone from occasional use […]

Chapter 239 – Nonpenetrating Glaucoma Surgery

Chapter 239 – Nonpenetrating Glaucoma Surgery   ELIE DAHAN TAREK SHAARAWY ANDRE MERMOUD JEFFREY FREEDMAN           DEFINITION • Nonpenetrating glaucoma surgery (NPGS) refers to drainage procedures that restore aqueous humor filtration through a natural membrane, namely the trabecular meshwork. NPGS includes all the different surgical techniques previously named: trabeculectomy ab-externo, nonpenetrating […]

Chapter 237 – Cyclodestructive Procedures in Glaucoma

Chapter 237 – Cyclodestructive Procedures in Glaucoma   UNDRAA ALTANGEREL MARLENE R. MOSTER TAREK M. EID   INTRODUCTION The goal of glaucoma surgery is to lower the intraocular pressure (IOP) predictably, either by maximizing outflow (as in filtration and tube-shunt surgery) or by decreasing inflow (as with cyclodestructive procedures). The destruction of the ciliary body […]

Chapter 234 – New (Pending) Glaucoma Medical Therapy

Chapter 234 – New (Pending) Glaucoma Medical Therapy   WILLIAM C. STEWART   INTRODUCTION Ophthalmologists are fortunate to witness the introduction in recent years of several new pharmaceutical products to help manage elevated intraocular pressure (IOP). In general, these drugs are new compounds within existing classes of medicines already in use or combinations of currently […]

Chapter 233 – Current Medical Management of Glaucoma

Chapter 233 – Current Medical Management of Glaucoma   RONALD L. GROSS   INTRODUCTION The armamentarium for the medical treatment of glaucoma recently experienced an unprecedented expansion of available agents. Years ago, the choice was limited to miotics, epinephrine (adrenaline), and oral carbonic anhydrase inhibitors. The introduction of topical ß-blockers in the 1970s was a […]

Chapter 232 – Which Therapy to Use in Glaucoma?

Chapter 232 – Which Therapy to Use in Glaucoma?   CLIVE MIGDAL           DEFINITION • The aim of glaucoma therapy is to preserve visual function with minimal side effects.   KEY FEATURE • The choice of therapy (alone or in combination) for patients who have open-angle glaucoma includes medical treatment, laser […]

Chapter 231 – When to Treat Glaucoma

Chapter 231 – When to Treat Glaucoma   REBECCA S. WALKER JODY R. PILTZ–SEYMOUR   INTRODUCTION The decision to initiate therapy to lower eye pressure is a very serious one that has far-reaching consequences. Once started, therapy generally is continued for the rest of the patient’s life. Patients may be subjected to untoward side effects, […]

Chapter 227 – Post-Traumatic Glaucoma

Chapter 227 – Post-Traumatic Glaucoma   STANLEY J. BERKE           DEFINITION • Elevated intraocular pressure secondary to ocular trauma.   KEY FEATURES • Hyphema. • Angle recession.   ASSOCIATED FEATURES • Rebleeding. • Corneal blood staining. • Ghost cell glaucoma. • Gonioscopic angle deformities.       INTRODUCTION Elevated intraocular pressure […]

Chapter 226 – Ocular Inflammatory and Steroid-Induced Glaucoma

Chapter 226 – Ocular Inflammatory and Steroid-Induced Glaucoma   IVAN GOLDBERG           DEFINITION • Characteristic glaucomatous optic neuropathy associated with ocular inflammation or exposure to corticosteroids.   KEY FEATURES • Optic disc pallor and cupping. • Nerve fiber bundle perimetric defects. • Evidence of inflammation involving one or more global tissues. […]